Towards a new understanding and classification of chondrogenic neoplasias of the skeleton--biochemistry and cell biology of chondrosarcoma and its variants
- PMID: 12242518
- DOI: 10.1007/s00428-002-0641-x
Towards a new understanding and classification of chondrogenic neoplasias of the skeleton--biochemistry and cell biology of chondrosarcoma and its variants
Abstract
Despite substantial knowledge on the clinicopathology of chondrogenic skeletal neoplasms, only limited insights into the biology of the different tumor variants are available. There are virtually no established molecular markers for identification and classification of these neoplasms. In this paper, we present a systematic review of the biochemistry and cell biology of chondrogenic neoplasms of the bone focussing on our own recent investigations. The hallmark of all differentiated chondrogenic tumors is the presence of neoplastic chondrocytic cells responsible for the formation of the characteristic cartilaginous tumor matrix. These cells can show the full differentiation potential of physiologic chondrocytes depending on the tumor entity investigated. The high phenotypic diversity of physiologic chondrocytes explains the previously poorly understood, striking heterogeneity of the neoplastic cells and their surrounding extracellular matrix not only between different but also within chondrogenic tumors. In our studies, tumor classifications, so far based only on histomorphological criteria, were either confirmed or corrected: mesenchymal chondrosarcomas represent the prototypic neoplasm of pre-chondrogenic undifferentiated cells undergoing multifocal chondrocytic differentiation. Enchondromas, osteochondromas, and conventional chondrosarcomas are neoplasms of multi-phenotypically differentiated chondrocytes. Clear cell chondrosarcomas appear to be neoplasms of hypertrophic chondrocytic cells. A peculiar biology is displayed by dedifferentiated chondrosarcomas, which at least in most cases show neither "anaplasia" nor "dedifferentiation", but most likely "transdifferentiation" of part of the neoplastic cells to a cellular phenotype of a different mesenchymal differentiation lineage. Chondroblastomas do not show any chondroblastic differentiation at all. Our studies delineate molecular markers of chondrogenic neoplasms of the skeleton, which have the potential to be the basis of a new biology-orientated classification of skeletal neoplasms. The expression analysis of extracellular matrix genes, in particular of the collagen types, might be able to play herein a leading role in classification and diagnosis, similar to the cytokeratin subtypes or the CDs (cluster of differentiation) for the classification and diagnosis of neoplasms of the epithelia and the lymphatics.
Similar articles
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Intralesional vs. extralesional procedures for low-grade central chondrosarcoma: a systematic review of the literature.Arch Orthop Trauma Surg. 2018 Jul;138(7):929-937. doi: 10.1007/s00402-018-2930-0. Epub 2018 Apr 10. Arch Orthop Trauma Surg. 2018. PMID: 29633075
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.Elife. 2025 May 23;14:RP100887. doi: 10.7554/eLife.100887. Elife. 2025. PMID: 40407808 Free PMC article.
Cited by
-
Dedifferentiated chondrosarcoma of the lung: report of a case.Surg Today. 2011 Feb;41(2):251-4. doi: 10.1007/s00595-009-4240-1. Epub 2011 Jan 26. Surg Today. 2011. PMID: 21264763
-
Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies.Invest New Drugs. 2012 Aug;30(4):1782-90. doi: 10.1007/s10637-011-9663-z. Epub 2011 Apr 16. Invest New Drugs. 2012. PMID: 21499733
-
Dedifferentiated Chondrosarcoma: Diagnostic Controversies and Emerging Therapeutic Targets.Curr Oncol Rep. 2023 Oct;25(10):1117-1126. doi: 10.1007/s11912-023-01441-1. Epub 2023 Aug 21. Curr Oncol Rep. 2023. PMID: 37603119 Review.
-
Symptomatic loosening of a total knee arthroplasty caused by a tibial chondrosarcoma - a case report.Springerplus. 2014 Jun 24;3:308. doi: 10.1186/2193-1801-3-308. eCollection 2014. Springerplus. 2014. PMID: 24995155 Free PMC article.
-
Dedifferentiated chondrosarcoma: our clinico-pathological experience and dilemmas in 25 cases.J Cancer Res Clin Oncol. 2008 Feb;134(2):147-52. doi: 10.1007/s00432-007-0262-5. Epub 2007 Jul 25. J Cancer Res Clin Oncol. 2008. PMID: 17653766 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical